Horm Metab Res 2023; 55(06): 388-394
DOI: 10.1055/a-2065-0845
Original Article: Endocrine Care

Does the Association of Hashimoto's Thyroiditis with Differentiated Thyroid Cancer Really Have a Protective Role?

Ahmet Numan Demir
1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Zehra Kara
1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Cem Sulu
1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Serhat Uysal
1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Serdar Sahin
1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Guldana Zulfaliyeva
2   Department of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Oznur Aydin Atar
2   Department of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Nahida Valikhanova
2   Department of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Tulin Ozturk
3   Department of Medical Pathology, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Hande Mefkure Ozkaya
1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
,
Mustafa Sait Gonen
1   Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
› Author Affiliations

Abstract

The study is an investigation of aggressive tumor features, prognosis, and disease-specific mortality rates of differentiated thyroid cancer (DTC) in the presence of concomitant Hashimoto’s Thyroiditis (HT). The data of patients with DTC followed in our tertiary care center between 2000–2022 were analyzed. Variables such as patient age, gender, preoperative serum autoantibody levels, tumor characteristics, and treatment modalities were obtained from medical records. The diagnosis of HT was based either on the presence of a positive result in the pathological examination and/or on antibody positivity. A total of 637 patients [mean±SD age, 44.9±13.5 years; 485 women [76.1%)] were included in the analysis. The overall prevalence of coexistent HT was 22.9% (n=146). The disease-specific mortality associated with DTC was 2.9%. DTC patients with HT compared to those without; have more positive lymphovascular invasion (p<0.001), and lymph node metastases (p<0.001). According to the Kaplan–Meier curves, disease-specific survival rates among DTC patients without HT were significantly higher than patients with HT (log-rank p=0.002). The disease-specific mortality rate was 4.79% in DTC patients with HT, it was 1.43% in those without HT. Hashimoto thyroiditis was not associated with a 10-year recurrence-free survival (p=0.059). Differentiated thyroid cancers with concomitant HT are associated with some aggressive tumor features (such as lymphovascular invasion and nodal metastasis) and lower survival. In staging systems based on tumor risk factors, it may be useful to evaluate the presence of concomitant HT as a prognostic factor.

Supplementary Material



Publication History

Received: 24 November 2022
Received: 29 March 2023

Accepted: 29 March 2023

Accepted Manuscript online:
29 March 2023

Article published online:
09 May 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1-133
  • 2 Haddad RI, Nasr C, Bischoff L. et al. NCCN guidelines insights: Thyroid carcinoma, version 2.2018. J Natl Compr Canc Netw 2018; 16: 1429-1440
  • 3 Craig SJ, Bysice AM, Nakoneshny SC. et al. The identification of intraoperative risk factors can reduce, but not exclude, the need for completion thyroidectomy in low-risk papillary thyroid cancer patients. Thyroid 2020; 30: 222-228
  • 4 Adam MA, Pura J, Gu L. et al Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg 2014; 260: 601-605 discussion 605–607
  • 5 Benvenga S, Trimarchi F. Changed presentation of Hashimoto's thyroiditis in North-Eastern Sicily and Calabria (Southern Italy) based on a 31-year experience. Thyroid 2008; 18: 429-441
  • 6 Feldt-Rasmussen U, Rasmussen AK. Autoimmunity in differentiated thyroid cancer: significance and related clinical problems. Hormones (Athens) 2010; 9: 109-117
  • 7 Anil C, Goksel S, Gursoy A. Hashimoto's thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 2010; 20: 601-606
  • 8 Kim EY, Kim WG, Kim WB. et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2009; 71: 581-586
  • 9 Kebebew E, Treseler PA, Ituarte PH. et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001; 25: 632-637
  • 10 Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 1955; 70: 291-297
  • 11 Moon S, Chung HS, Yu JM. et al. Associations between Hashimoto thyroiditis and clinical outcomes of papillary thyroid cancer: A meta-analysis of observational studies. Endocrinol Metab (Seoul) 2018; 33: 473-484
  • 12 Dvorkin S, Robenshtok E, Hirsch D. et al. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimoto's thyroiditis. J Clin Endocrinol Metab 2013; 98: 2409-2414
  • 13 Kashima K, Yokoyama S, Noguchi S. et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 1998; 8: 197-202
  • 14 Marotta V, Sciammarella C, Chiofalo MG. et al. Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer 2017; 24: 485-493
  • 15 Vasileiadis I, Boutzios G, Charitoudis G. et al. Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol 2014; 21: 2725-2732
  • 16 Shen CT, Zhang XY, Qiu ZL. et al. Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword?. Endocrine 2017; 58: 176-183
  • 17 Iliadou PK, Effraimidis G, Konstantinos M. et al. Chronic lymphocytic thyroiditis is associated with invasive characteristics of differentiated thyroid carcinoma in children and adolescents. Eur J Endocrinol 2015; 173: 827-833
  • 18 Zhang Y, Ma XP, Deng FS. et al. The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer. World J Surg Oncol 2014; 12: 277
  • 19 Uhliarova B, Hajtman A. Hashimoto's thyroiditis - an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol 2018; 84: 729-735
  • 20 Zhu F, Shen YB, Li FQ. et al. The effects of Hashimoto thyroiditis on lymph node metastases in unifocal and multifocal papillary thyroid carcinoma: A retrospective Chinese cohort study. Medicine (Baltimore) 2016; 95: e2674
  • 21 Adam MA, Pura J, Goffredo P. et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol 2015; 33: 2370-2375
  • 22 Pisanu A, Piu S, Cois A. et al. Coexisting Hashimoto's thyroiditis with differentiated thyroid cancer and benign thyroid diseases: indications for thyroidectomy. Chir Ital 2003; 55: 365-372
  • 23 Okayasu I, Fujiwara M, Hara Y. et al. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer 1995; 76: 2312-2318
  • 24 Matsubayashi S, Kawai K, Matsumoto Y. et al. The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 1995; 80: 3421-3424
  • 25 Yoon YH, Kim HJ, Lee JW. et al. The clinicopathologic differences in papillary thyroid carcinoma with or without co-existing chronic lymphocytic thyroiditis. Eur Arch Otorhinolaryngol 2012; 269: 1013-1017
  • 26 Paulson LM, Shindo ML, Schuff KG. Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2012; 147: 444-449
  • 27 Zeng R, Lyu Y, Niu H. et al. FoxP3 promotes lymph node metastasis in patients with papillary thyroid carcinoma complicated with Hashimoto's thyroiditis. Transl Cancer Res 2020; 9: 1337-1350